PALO ALTO, Calif., May 17, 2013 /PRNewswire/ – Cellular Biomedicine Group (CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To date the trial has had no Severe Adverse Effect
SYDNEY, AUSTRALIA–(Marketwired – May 16, 2013) – Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN:US74154B2034) (“Prima”, the “Company”) has announced in pursuant to shareholder approval received at yesterday’s general meeting, the Company has today issued 13,287,500 fully paid ordinary shares (Shares) to its directors and 1,250,000 Shares to certain institutional investors on the same terms and price as the recently completed Share purchase … Read more
Actinium’s lead drug candidate and technology platforms will be discussed in presentations at the TAT Symposium in Oak Ridge, TN June 4 – 6, 2013
NEW YORK, May 16, 2013 /PRNewswire/ – Actinium Pharmaceuticals, Inc. (ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target Alpha Therapy (TAT) international symposium … Read more
NEW YORK, May 16, 2013 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE MKT:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of patent grant in Malaysia (MY-147516-A) and notice of recommendation for patent allowance in the Philippines (1-2008-501074). These patents are in
LOS ANGELES–(BUSINESS WIRE)–ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Rα2) in cancer immunotherapy. IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. … Read more
– Company Reports Record Revenue through Continued Execution of Growth Plan -
LOS ANGELES–(BUSINESS WIRE)–Targeted Medical Pharma, Inc. (TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its first quarter ended March 31, 2013. The Company posted record quarterly revenue of $2.811 million for the first … Read more
Q1 2013 Revenues Increased Over 450% Compared to Q1 2012
MINNEAPOLIS, May 15, 2013 /PRNewswire/ – BioDrain Medical, Inc. (BIOR) (the “Company”), producer of the FDA approved STREAMWAY™ System for automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, today reported its results for the first quarter ended March 31, 2013.
Key Highlights:
- Revenues of $127,727 for
PRINCETON, N.J., May 15, 2013 /PRNewswire/ – Soligenix, Inc. (SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn’s … Read more
Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man
BLUE BELL, Pa., May 14, 2013 /PRNewswire/ – Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio’s SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled “Category A” bioterrorism agents by the U.S. government, the … Read more
NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE MKT:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy (“PCT”), will present at multiple conferences in May.
8th Annual World Stem Cells and Regenerative Medicine Congress 2013
- Date and Time: Wednesday, May 22, 2:25 PM BST
